Lundbeck's big reorg will help fund R&D on new antipsychotic med

As Lundbeck cuts staff and reshuffles R&D, one of its drug candidates has come out a winner. The Danish drugmaker will go solo on developing a schizophrenia med, Lu AF35700, using its reorganized balance sheet to help fund its R&D advance out of early-stage study. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.